JP Morgan Chase’s Principia Biopharma Inc. Common Stock PRNB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q3
Sell
-74,955
Closed -$4.48M 5995
2020
Q2
$4.48M Sell
74,955
-6,414
-8% -$396K ﹤0.01% 2534
2020
Q1
$4.83M Sell
81,369
-69,222
-46% -$4.04M ﹤0.01% 2291
2019
Q4
$8.25M Buy
150,591
+11,325
+8% +$423K ﹤0.01% 2279
2019
Q3
$3.93M Buy
139,266
+5,587
+4% +$205K ﹤0.01% 2893
2019
Q2
$4.44M Sell
133,679
-12,197
-8% -$381K ﹤0.01% 2740
2019
Q1
$4.96M Sell
145,876
-3,673
-2% -$117K ﹤0.01% 2588
2018
Q4
$4.1M Buy
149,549
+134,399
+887% +$3.46M ﹤0.01% 2735
2018
Q3
$442K Buy
+15,150
New +$428K ﹤0.01% 4336

Other funds holding PRNB

JP Morgan Chase's PRNB Position: Q3 2020 in Review

JP Morgan Chase sold out of Principia Biopharma Inc. Common Stock (PRNB) in Q3 2020, closing a stake of 74,955 shares — an estimated $4.48M sold.

JP Morgan Chase first reported a position in PRNB in Q3 2018 and held it in 8 quarters. The position peaked at $8.25M in Q4 2019. 9 funds tracked by Wall St. Rank hold PRNB as of Q3 2020.

  • JP Morgan Chase reported no remaining Principia Biopharma Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • JP Morgan Chase sold 74,955 Principia Biopharma Inc. Common Stock shares in Q3 2020, an estimated $4.48M.
  • JP Morgan Chase first reported a position in Principia Biopharma Inc. Common Stock in Q3 2018 and held it in 8 quarters.
  • JP Morgan Chase's Principia Biopharma Inc. Common Stock position peaked at $8.25M in Q4 2019.
  • 9 funds tracked by Wall St. Rank held Principia Biopharma Inc. Common Stock as of Q3 2020.

Based on JP Morgan Chase's 13F filing for Q3 2020, filed 12 Nov 2020.